a website banner telling users to subscribe to it's newsletter

Marinomed Biotech Plans to Launch Carragelose Eye Drops in 2024

Marinomed Biotech Plans to Launch Carragelose Eye Drops in 2024

June 15, 2023

Marinomed Biotech has announced the introduction of a new Carragelose eye drop product, known as MAM-1001-3, to their existing Carragelose OTC portfolio. The product has obtained certification under the Medical Device Directive (MDD) and is currently undergoing preparations for marketing. Marinomed also has plans to obtain certification under the new Medical Device Regulation (MDR) through a clinical trial, ensuring compliance and regulatory approval.

The company is actively seeking partnerships for distribution within the EU, with an initial partnership already established for the eye drops. The anticipated market launch in Austria is set for the first half of 2024. Furthermore, Marinomed has initiated a business development process to identify additional partners for global marketing of the product.

“The introduction of Carragelose eye drops is a logical addition to our current OTC portfolio. This asset has an upright certification and is ready for partnering and marketing, thus will be generating revenues in the near to medium term,” explains Andreas Grassauer, CEO of Marinomed. “The product is intended to provide relief for dry eyes. Carragelose has excellent moisturizing properties and an outstanding safety profile. In addition, Carragelose is well known for its virus-blocking effectiveness.”

Carragelose® is a sulfated polymer derived from red seaweed, known for its unique properties as a broad-spectrum antiviral compound. It has been proven effective and safe in preventing and treating various viral respiratory infections. Extensive clinical and preclinical studies have demonstrated that Carragelose® creates a protective barrier on the mucosa, effectively blocking viral infections. Furthermore, laboratory and clinical data have shown its ability to inhibit the spread of SARS-CoV-2.[1],[2]

Marinomed holds the intellectual property rights for Carragelose® and has obtained licenses for its marketing in Europe, North America, Australia, and selected regions in Asia and Latin America. To explore Marinomed's portfolio of nasal sprays and oral products containing Carragelose®, please visit: https://www.carragelose.com/en/portfolio/launched-products. Scientific publications on Carragelose® can be accessed at: https://www.carragelose.com/en/publications.


1. https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM

2. https://www.marinomed.com/en/news/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1